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Abstract
Neuroblastoma (NB) is the most common extracranial solid neoplasm of infancy and childhood. Whereas most
low-risk patients do well, children with high-risk tumors often fail intensive treatment. Identification of novel bio-
markers is critical to improve prognostication, tailor therapy, and develop new therapeutic targets. Differential
RNA-level expression between tumor cells with neuroblastic (N-type) and Schwannian stromal (S-type) phenotypes
was used to identify genes of potential interest based on tumor cell type–specific regulation. Gene expression micro-
array analysis revealed marked differences between N-type and S-type cells in their levels of BCL6 messenger RNA, a
transcriptional regulator overexpressed in a variety of hematopoieticmalignancies. S-type cells express higher levels of
Bcl6 RNA and protein than N-type, and protein levels are significantly limited by proteasome function. An NB tumor
tissuemicroarray linked to clinicopathologic data was immunohistochemically stained to measure Bcl6 protein levels.
Bcl6 was detected in both the neuroblastic and Schwannian stromal regions, as distinguished histologically, and
correlated with outcome. We found that expression in neuroblastic regions differentiates outcomes, in that Bcl6 ex-
pression in neuroblastic regions is associated with increased time to relapse and increased overall survival compared
with absent expression in neuroblastic regions, regardless of Schwannian stromal expression. Thus, our findings sug-
gest that Bcl6may be useful as a prognosticmarker andmight represent a potential therapeutic target for high-risk NB.
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Introduction
Neuroblastoma (NB), a tumor derived from neural crest cells [1], is the
third most common pediatric cancer [2], accounting for approximately
7% to 10% of all childhood malignancies [3]. It is also the most
common solid extracranial neoplasm of infancy and childhood [4]
and accounts for approximately 15% of all childhood cancer deaths
[5]. Because the clinical behavior of this disease varies widely, from
spontaneous regression in very young children to the emergence of
chemotherapy-resistant aggressive disease in older children with high-
stage disease [6], optimal selection of treatment relies on tumor-specific
characteristics that predict outcome tomaximize clinical responses while
minimizing exposure to toxic drug regimens.
Contemporary practice uses risk-based treatment planning to assign
patients to low-risk, intermediate-risk, or high-risk groups based on
factors including age at diagnosis, tumor stage, International Neuro-
blastoma Pathology Committee’s (revised Shimada) histopathologic
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classification, DNA index, amplification of theMYCN oncogene within
tumor tissue, and unbalanced loss of heterozygosity for chromosome 1p
or 11q [7]. Whereas patients with low-risk disease are treated with sur-
gery alone and have a 5-year survival exceeding 95% [6], patients in
the high-risk subgroup have less than a 40% chance of long-term sur-
vival despite a dose-intensive multimodal therapy [8]. The outcome for
intermediate-risk patients is less certain with reports showing that sub-
groups can be described to have excellent survival rates when surgery is
combined with nonaggressive chemotherapy, whereas others treated in
the same way do poorly [9].
The heterogeneity of cell types comprising NB tumors allows for the
possibility that therapeutic response is affected by differential sensitivity
of tumor cell types to drugs used to treat this disease. Neuroblastic and
Schwannian stromal cell–rich regions in tumors can be distinguished
by histological criteria [10] and by cell type–specific marker expres-
sion [11]. For example, cells in neuroblastic regions express high levels
of neurotransmitter biosynthetic enzymes [12] and the oncogenes
BCL2 and MYCN. Schwannian stromal cells, however, are collagen-
synthesizing cells that have little or no neurotransmitter synthetic ac-
tivity [13,14]. These cell types have different and perhaps opposing
roles in tumor growth. Evidence supports a range of functions for
the bland Schwannian stromal cells from the production of growth-
inhibitory factors that limit tumor spread to transdifferentiation into
malignant-acting neuroblasts [15–18]. Most importantly, cell lines
derived from high-risk NB tumors can mimic one or both of these
two phenotypes that respond differently to chemotherapy in vitro [19].
The fact that NB tumors are composed of a mixed population of
cells that can be distinguished both molecularly and functionally sug-
gests that differences in gene expression between these cell types
could be used to identify candidate biomarkers and therapeutic tar-
gets with particular relevance to one or the other cell type. Toward
this goal, we compared the gene expression in N- and S-type NB cell
lines. Among the differentially expressed genes were several genes
encoding proteins already established as markers specific for either
N- or S-type cells. Unexpectedly, we found that Bcl6 was among
those genes with a pattern of differential expression matching known
S-type cell markers. Literature review showed that Bcl6 messenger
RNA (mRNA) was overexpressed in other sets of published NB micro-
array data [20–22], yet this protein product has not previously been
reported to be expressed in NB or in other neuronal tumors. There-
fore, we further studied this phenomenon and discovered that tumors
with Bcl6 expression in neuroblastic cell–rich regions present more
favorable outcomes. These results suggest that the expression of Bcl6
in NB tumors provides prognostic information, an association that
can be further explored for use as a marker by which to stratify treat-
ment decisions. Moreover, this work suggests the possibility that Bcl6
plays previously unexpected roles in tumorigenesis and/or treatment
responses of NB.
Materials and Methods
Cell Lines
Nine NB cell lines were used for microarray analyses: five N-type
(neuroblastic phenotype: IMR-32, LA1-55n, SHSY-5Y, SK-N-BE(2)-
M17, and SH-IN [FSK-treated]), two S-type (Schwannian stromal
phenotype: SH-EP and SMS-KCNs), and two I-type (intermediate
phenotypes, with features of both N- and S-type cells: SH-IN and
SK-N-BE(2)c-T38) cell lines. Twelve cell lines (SHSY-5Y, IMR-32,
GOTO, SK-N-BE(2)-M17, LA1-55n, SMS-KCN-69n, SH-EP, LA1-
5s, WSN, CA-2E, SK-N-SH310, and SK-N-AS) were used in Western
blot analysis. Cell lines were grown in minimal essential medium sup-
plemented with 10% fetal bovine serum, 2 mM glutamine, 100 units/
ml penicillin, and 100 μg/ml streptomycin in a humidified 5% CO2
incubator at 37°C. IMR-32 medium was further supplemented with
1 mM pyruvate and 0.075% NaHCO3.
RNA Extraction and cDNA Synthesis
The isolation of RNA from NB cell lines was carried out using the
Qiagen RNAeasy kit (Qiagen, Valencia, CA) according to the manufac-
turer’s recommended protocols. The isolated RNA was purified with
DNase (RNase-Free DNase Set, Qiagen) to digest genomic DNA ac-
cording to the manufacturer’s instructions. The integrity of RNA was
visually assessed by conventional agarose gel electrophoresis. mRNA
was reverse-transcribed into cDNA using TaqMan Reverse Transcrip-
tion Reagents (Applied Biosystems, Branchburg, NJ) according to
the manufacturer’s protocol. Parallel control reactions without the ad-
dition of reverse transcriptase were performed for each sample. The
gene-specific reverse transcription–polymerase chain reaction (RT-
PCR) products were visualized with ethidium bromide staining after
agarose gel electrophoresis.
Real-time Quantitative RT-PCR
Quantitative RT-PCR (QRT-PCR) analysis was performed using an
ABI 7700 sequence detector (Applied Biosystems). For the amplifica-
tion of Bcl6 and the internal control GAPDH, we used TaqMan probe
labeled with 6-carboxyfluorescein from Applied Biosystems. The stan-
dard curves for Bcl6 and GAPDH were prepared using serial dilution
of known concentrations of RNA (0.5,2.5,12.5, 62.5, 312.5, and
1562.5 pg) from Ramos cells (a Bcl6-overexpressing human Burkitt’s
lymphoma line), which was also reverse-transcribed and amplified in
a similar manner as that of RNA from NB cell lines (previously men-
tioned). The quantity of Bcl6 mRNA was calculated after normalizing
for the internal control GAPDH.
Immunoblot Analysis
Nuclear protein (20 μg) fromNB cell lines was resolved by 8% SDS-
PAGE and transferred to polyvinylidene fluoridemembrane (Invitrogen,
Grand Island, NY). Membranes were blocked with 5% milk and
immunoblotted with anti-Bcl6 polyclonal antibody (Santa Cruz Bio-
technologies, Santa Cruz, CA) at a 1:1000 dilution. The blots were vi-
sualized by chemiluminescence using a horseradish peroxidase–linked
anti–rabbit immunoglobulin G secondary antibody (GE Healthcare,
Buchinghamshire, United Kingdom) diluted at 1:5000. Anti–cAMP re-
sponse element-binding protein (Upstate Biotechnology, Lake Placid,
NY) was used as a loading control. For experiments evaluating Bcl6
posttranslational processing, cells were pretreated for 18 hours with
specific proteosome inhibitors MG132 (10 mM; Calbiochem, La Jolla,
CA) dissolved in dimethylsulfoxide or bortezomib (50 nM; Velcade,
Millenium, Boston, MA).
Oligonucleotide Microarray Hybridization and Analysis
Preparation of cRNA from total RNA, hybridization, scanning, and
image analysis were performed according to the manufacturer’s proto-
col and as previously described [23]. We used commercially available
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oligonucleotide arrays (HG_U133A; Affymetrix, Santa Clara, CA) con-
taining 22,283 probe sets. Each probe set typically contains 11 perfectly
matched 25-base-long probes (PMs) as well as 11 mismatch probes
(MMs) that differ from the PM probes at the central base. Using
publicly available software [24], we computed the average of the PM −
MM differences for each probe set on each array after discarding the
largest and smallest 20% of the PM − MM differences, and scaled
the data for each array to give a mean of 1500 units. Data were then
quantile-normalized to make the values of 99 evenly spaced quantiles
(at 0.01, 0.02,…, 0.99) agree across all of the arrays.We log-transformed
values using log [max(x + 50; 0) + 50]. Conservative average fold differ-
ences were computed based on the differences in log-transformed data.
Tissue Microarray Construction
Tissue specimens were obtained from the University of Michigan
Department of Pathology archives under the approval of the Institu-
tional Review Board. Tissue arrays were constructed using three
1.0-mm cores taken from 48 paraffin-embedded, formalin-fixed neu-
roblastic tumors (32 NBs, 10 intermixed and nodular ganglioneuro-
blastomas (GNBs), and 6 ganglioneuromas (GNs)), 5 normal adrenal
glands, and 7 other neural crest–derived (melanoma, pheochromocy-
toma, paraganglioma, and schwannoma). The histologic classification
of archived tumor specimens was available, but all specimens were
blindly reviewed by a single pathologist (J.A.J.) and classified according
to current standards using the International Neuroblastoma Pathology
Committee’s classification [10,25]. Core sampling was performed to
ensure that optimal representation of both neuroblastic and stromal
components was present. Completed array blocks were cured at 37°C
for at least 24 hours, then heated at 52°C for 15 minutes, and rapidly
cooled in an ice water bath. Multiple 5-μm tissue sections were cut
from each block, with every 10th section stained with hematoxylin/
eosin for morphologic assessment and comparison to adjacent immuno-
stained levels.
Protein Expression Analysis
Immunohistochemistry was performed using commercially available
monoclonal antibodies and standard manufacturer’s protocols on a
Ventana automated stainer. Briefly, slides were incubated with anti-
Bcl6 (PG-B6p; Dako Cytomation, Carpinteria, CA) at a 1:20 dilution
after a 20-minute pretreatment in a high-pH buffer at 95°C. Signals
were evaluated for tumoral distribution (neuroblastic cells vs Schwannian
stromal cells), cellular distribution (nuclear vs cytoplasmic), and inten-
sity (semiquantitatively graded as 0, 1+, 2+, or 3+). The neuroblastic
component was defined as any or all of the following: neuroblasts, im-
mature gangliocytoid cells, and mature ganglion cells; the stromal com-
ponent was defined as spindled cells with scant clear to eosinophilic
cytoplasm embedded in a loose connective tissue matrix resembling
Schwann cells or perineurium. Specimens excluded from analysis in-
cluded those tumor array cores with insufficient tissue or missing sec-
tions, those that were necrotic, and those with insufficient neuroblastic
or stromal components for evaluation. For each evaluated specimen,
the mean neuroblastic component staining, the mean stromal compo-
nent staining, and the mean component staining difference were cal-
culated for all three cores.
Patient Data
Tumor array specimens from 48 patients were evaluable and included
in the analysis. Patient characteristics included tumor specimens from
23 females and 25 males, ranging in age from 0 to 16 years. The mean
age at diagnosis was 3.0 years, and themedian age was 2.5 years. Twenty-
five tumor specimens were from stage I or II patients, 5 from stage III
patients, and 17 from stage IV patients. There was one stage IVS patient
included in this analysis. Length of available follow-up data ranged
from1 to 17 years from the time of diagnosis. Thirty-seven patients were
alive at the time of the study with mean follow-up of 6.7 years. Of the
32 NB patients, 13 had favorable histologic diagnosis and 19 had un-
favorable histologic diagnosis. Of the 10 GNB patients, 7 had favorable
histologic diagnosis, 2 had unfavorable histologic diagnosis, and 1 patient
had missing data precluding proper classification. The GN group in-
cluded six patients, all with favorable histologic diagnosis.
Statistical Analysis
The goal of the analysis was exploratory in nature. Clinical outcomes
were correlated to the intensity of the expression and the presence of
the expression in neuroblastic and stromal regions. For Bcl6 intensity
analysis, the subject-level average was used in correlation with the out-
comes. Subject-level average was computed by averaging the intensity
of Bcl6 expression from cores on tissue microarray that were from the
same subject. The intensity in the neuroblastic and stromal regions
and the differential expression between neuroblastic and stromal re-
gions were evaluated. For the analysis on the presence, Bcl6 expression
was grouped into four categories based on the presence (+) or absence
(−) of expression in S-type cells and N-type cells. The four possible
groupings were as follows: S+/N+ (both stromal and neuroblastic cell
Bcl6 expression), S+/N− (stromal cell expression only), S−/N+ (neuro-
blastic expression only), or S−/N− (both stromal and neuroblastic cells
negative). Covariates of interest included: MYCN (amplified, inde-
terminate, and normal), clinical stage (I, II, III, and IV), and tumor
histologic diagnosis (NB, GNB, or GN). Outcomes analysis included
Bcl6 expression in relation to overall survival and time to recurrence
from end of therapy (event-free survival). Spearman rank correlation
coefficient was used to assess univariate association between Bcl6 ex-
pression intensity and covariates of interest, whereas Fisher exact test
was used to assess univariate associations between four-group N and
S regions presence of Bcl6 expression and covariates of interest. The
Kaplan-Meier method and log-rank test were used to compare the ho-
mogeneity of survival rates between categories of Bcl6 expression, the
intensity of Bcl6 expression, as well as discrete covariates. Time to re-
currence was defined as the time when NB relapse was documented.
Subjects who did not recur at last follow-up or who died for reasons
other thanNB recurrence were censored from the analysis. All statistical
analyses were done using SAS v9.0 (Carey, North Carolina). A 2-tailed
P value of 0.05 or less was considered to be statistically significant.
Results
Bcl6 Is Expressed in NB
RNA expression profiles of nine NB cell lines (five N-type, two
S-type, and two I-types) and three NB tumors were generated using
the Affymetrix platform. Genes that were differentially expressed
between N- and S-type cell line groups with a fold change ≥5 (P <
.01) were identified yielding 411 probe sets that included several
genes already known to be expressed specifically in either the neuroblas-
tic or the stromal components of neuroblastic tumors, validating the
strategy of using differential expression to identify cell type–specific
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gene expression. Results in Figure 1 show expression data from a select
subset of these genes. As expected, vimentin, collagen type IV, and
fibronectin, known stromal markers [26], were expressed at signifi-
cantly higher levels in S-type cell lines, whereas neurofilament and
chromogranin A, markers of neuroblastic cells [27], were expressed
at higher levels in N-type cells. Surprisingly, the expression of Bcl6, a
transcriptional regulator implicated in B-cell development and lym-
phomagenesis [28], was differentially expressed with a high-level
expression in S-type cells, having an N/S ratio of 0.05, similar to
known S-type–specific markers. Moreover, Bcl6 expression was detected
in each of the three NB tumor specimens (NB1, NB2, and NB3 in
Figure 1), which contained mixed populations of stromal and neuro-
blastic cells.
Bcl6 mRNA Expression in an Expanded Panel of NB
Cell Lines
To confirm the presence and differential expression of Bcl6mRNA in
NB cells, we isolated RNA from a larger panel of 12 well-characterized
NB cell lines (6 S-type and 6N-type). RNAwas reverse-transcribed, and
cDNAwas amplified using either Bcl6 or β-actin–specific primer sets as
described in the Materials and Methods section. Consistent with our
microarray results, ethidium bromide–based detection of PCR products
identified Bcl6message in each of theNB cell lines analyzed (Figure 2A).
As a group, expression in S-type cell lines seemed higher than in N-type
cell lines, although Bcl6 expression was not exclusive to S-type cells. In
several S-type lines, the level of Bcl6 expression was similar to the level
in Ramos cells, a human Burkitt’s lymphoma cell line in which Bcl6
expression controls growth and differentiation [29,30].
These results were confirmed by using QRT-PCR with normaliza-
tion to GAPDH as the internal control. As shown in Figure 2B, there
was a significantly higher expression of Bcl6 mRNA in S-type cells
(filled bars) than N-type cells (striped bars; P < .008). The difference
observed between N- and S-type cells for Bcl6 is similar in magnitude
to that of vimentin (Figure 2C), an S-type–specific marker [26].
Bcl6 Protein Expression in NB Cell Lines
Initial attempts to detect Bcl6 protein in NB cell lines showed that
even in cell lines with high levels of Bcl6 mRNA, Bcl6 protein levels
were barely detectable using standard immunoblot analysis techniques.
Previous reports suggest that Bcl6 protein expression in B cells is tightly
regulated by proteosomal processing [31]. Therefore, we hypothesized
that proteosomal degradation may limit Bcl6 protein levels in NB cell
lines. To test this possibility we treated cells with the proteosomal
inhibitors MG132 and bortezomib, both reversible inhibitors of the
chymotrypsin-like activity of the 26S proteasome [32,33]. Cells were
pretreated for 18 hours with the inhibitors before extracts were made,
and Bcl6 expression was determined. As shown in Figure 3A, Bcl6 pro-
tein levels increase in response to proteasome inhibition to an extent
that varies according to cell line and the inhibitor used. For example,
in SH-EP and SK-N-SH cells, Bcl6 expression increased in response
to MG132 but not bortezomib treatment. Interestingly, pretreatment
of N-type cell lines with proteasome inhibitors did not affect Bcl6 pro-
tein levels. These results suggest posttranslational processing leading to
proteosomal degradation may contribute to the regulation of Bcl6 in
NB similar to B-cell lymphoma [34].
Bcl6 Protein Expression in NB Tumors
Next, we extended our analysis to determine whether Bcl6 protein
was expressed in NB tumor tissue, and if so, whether there was differ-
ential expression between neuroblastic and Schwannian stromal cell–
rich regions. Tumor tissue microarrays comprising a panel of primary
NB tumors, normal adrenal glands, and other selected neural crest–
derived neoplasms were subjected to immunohistochemistry to detect
Bcl6 protein. Bcl6 staining was evaluated by scoring the signal intensity
using a grading system from 0 (no staining) to 3+ (marked expression).
Furthermore, in primary NB tumors, a separate score was determined
for neuroblastic and Schwann/stromal cell–rich regions.
Bcl6 is detected in normal adrenal glands at an average staining
intensity of 2.6, that is significantly greater than expression in either
neuroblastic (average intensity = 1.35) or stromal regions (average
Figure 1. Differential expression of N- and S-type marker genes and Bcl6. Expression level of Bcl6 and selected RNA previously shown
specific for neuroblastic (top panel) or Schwannian stromal cells (bottom panel) in a panel of N-type (IMR-32, LA1-55n, SHSY-5Y, SK-N-
BE(2)-M17, and SH-IN [FSK-treated]), S-type (SH-EP and SMS-KCNs), and I-type (SH-IN and SK-N-BE(2)c-T38) NB cell lines and in three
human NB tumor specimens (NB1, NB2, and NB3). Color indicates fold difference of each sample from the midpoint of the two means
for S- and N-type cells, with red indicating higher and green indicating lower expression. P values are from 2-tailed t tests, and the fold
difference indicates the ratio of average N-type to S-type expression values.
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intensity = 1.0) of NB tumors. Bcl6 expression in benign neural crest
tumors (paraganglioma, pheochromocytoma, and schwannoma) is also
greater (average intensity = 2.9) than in NB. Average expression in
melanoma, another malignant neural crest derived tumor, is 0.7. These
results suggest a pattern where malignant neural crest tumors have
lower Bcl6 expression than normal adrenal or benign tumors derived
from the neural crest.
Bcl6 protein expression in the NB tumor cores was correlated with
clinical and pathological factors relevant in establishing risk group as
well as predicting outcome. Forty-eight patients with available follow-
up data were included in this analysis. Median duration of follow-up
was 5.0 years (range, 1.3-17.5 years). Thirty-eight (79%) patients were
alive, 33 of 38 were in their first complete remission, and 5 of 38 who
had relapsed were in a subsequent complete remission. Ten patients
(21%) had died: nine of NB dissemination and one of treatment com-
plications. Of the 48 tumors included in this array, Bcl6 protein was
detected in 50% (24/48).
To determine whether expression varied between neuroblastic
and Schwannian stromal components, a subset of tumor samples
(Table 1) was selected based on copresence of sufficient neuroblastic
and Schwannian/stromal–rich regions to adequately assess expression in
each component separately (n = 20). The absence of either neuroblastic
Figure 2. Bcl6 RNA expression in N- and S-type NB cell lines. (A) Reverse transcription–polymerase chain reaction products of Bcl6 RNA
in NB cell lines detected by ethidum bromide staining. Lanes 1 to 6 and 7 to 12 are from the indicated N- and S-type cell lines, respectively;
lanes 13 and 14 are positive controls (Ramos cells and Bcl6 cDNA, respectively); lane 15 is a negative control using Ramos without reverse
transcriptase. β-Actin (lower panel) supports equivalent loading. (B) Q-RT-PCR comparing GAPDH-normalized Bcl6 transcript levels across
the 12 NB cell lines indicated (N-type lines shown as stripped bars and S-type as solid bars) shows significantly higher expression of Bcl6 in
S-type cells (P = .008, 2-tailed t test). (C) Quantitative RT-PCR for GAPDH-normalized vimentin transcript in the same 12 cell lines confirms
greater expression in S-type cell lines.
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or stromal regions in the remaining samples (n = 28) was a result of tech-
nical limitations whereby core sampling did not include a representative
heterogeneous specimen or in two instances where the primary tumor
did not contain any histologically definable stromal component. Table 1
shows a summary of Bcl6 staining according to cell type and tumor
histologic diagnosis. Of the 20 patient tumors with both neuroblastic
and Schwannian components, 12 were classified as NB, 5 as GNBs,
and 3 as GNs. This secondary analysis was completed by tabulating
whether Bcl6 was expressed in N and S regions separately and assigning
tumors to one of the following groups: N+/S+ (Bcl6 expression in both
neuroblastic and stromal regions), N+/S− (only neuroblastic regions
positive), N−/S+ (only stromal regions positive), or N−/S− (no Bcl6 ex-
pression in either region). Figure 4 shows a representative staining pat-
tern for each of the four subgroups. In 18 of 20 specimens, Bcl6 protein
was expressed in at least one of the histological subsets (neuroblastic or
stromal). In five tumors, expression was detected in both neuroblastic
and stromal regions (N+/S+). In eight tumors, Bcl6 expression was de-
tected only in neuroblastic regions (N+/S−), and in five tumors, Bcl6
expression was confined to the stromal regions (N−/S+). The intensity
of Bcl6 staining, when present, did not differ significantly between the
neuroblastic (average intensity = 1.35) and stromal regions (average
intensity = 1.0). Thus, although the pattern of Bcl6 expression in vitro
showed increased expression in S-type compared with N-type cell lines,
Bcl6 expression within tumor tissue was neither specific to nor increased
in the cells comprising the Schwannian stromal cell–rich regions.
The intensity of Bcl6 expression in either tumor component was
not significantly associated with overall survival (data not shown).
We then compared Bcl6 expression with the known prognostic vari-
ables important for NB risk stratification individually (MYCN status,
stage, and histologic diagnosis). There was no significant correlation
between Bcl6 expression and MYCN status or stage; however, a weak
Figure 3. Inhibitors of the proteasome increase Bcl6 protein in NB cells. Immunoblots of nuclear extracts to detect Bcl6 protein in S-type
cell lines (A) and N-type cell lines (B) either untreated or treated as indicated with MG132 (10 mM) or bortezomib (50 nM) for 18 hours.
Bcl6 is barely detectable in untreated cells and is increased in S-type but not in N-type cell lines with proteasome inhibition. Blot analysis
for CREB demonstrates approximately equivalent sample loading.
Table 1. Bcl6 Expression in Neuroblastic (N) and Schwannian Stromal (S) Tumor Regions Accord-
ing to Histologic Diagnosis.
N+/S+ N+/S− N−/S+ N−/S− Total
NB 3 2 5 2 12
GNB 1 4 0 0 5
GN 1 2 0 0 3
Total 5 8 5 2 20
GN indicates ganglioneuroma; GNB, ganglioneuroblastoma; NB, neuroblastoma.
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but significant correlation between Bcl6 expression and histologic di-
agnosis was demonstrated using Spearman correlation. In this analysis,
Bcl6 expression in neuroblastic regions was associated with favorable
histologic diagnosis. Conversely, increased Bcl6 expression in stromal
regions was associated with unfavorable histologic diagnosis. Impor-
tantly, when we compared the association between Bcl6 groups (N+/
S+, N−/S+, N+/S−, and N−/S−) and patients’ overall survival, Kaplan-
Meier analysis demonstrated that patients whose tumors had Bcl6
expression in the neuroblastic cells (N+/S+ and N+/S−) had a more
favorable outcome measured by overall survival (P = .038) (Figure 5A).
This similar trend was observed in the time to recurrence outcome,
but P value did not reach statistical significance at the 0.05 level (P =
.065; Figure 5B).
Discussion
This work identifies the presence of Bcl6 RNA and protein in NB
cells and human NB tumor tissue. To our knowledge, this is the first
report to identify the presence of Bcl6 protein in NB and that its pat-
tern of expression is associated with prognostic variables and outcomes.
Bcl6 is a transcriptional repressor that binds DNA through six zinc
fingers [35,36] and regulates transcription by interacting with a number
of other factors including Jun proteins, nuclear receptor corepressor,
Bcl6 corepressor, silencing mediator of retinoid and thyroid receptor,
and histone deacetylase family proteins through its amino-terminal
BTB domain (bric-a-brac, tramtrack, broad complex) [37–40]. Bcl6
has an important role in B-cell development. Its expression is low in
immature B cells, increases as these cells differentiate through the ger-
minal centers, and is then turned off when B cells terminally differen-
tiate into plasma cells [41,42]. In germinal centers, Bcl6 delays terminal
differentiation and allows cells to survive DNA double-strand breaks
that occur as the B-cell receptor gene is rearranged. Mechanistically,
this is accomplished by repression of ATR and TP53 transcription that
otherwise blocks B-cell proliferation and induces cell death [39,43].
By maintaining the proliferative potential of cells with DNA damage,
Bcl6 can support neoplastic transformation, consistent with observa-
tions that its expression is frequently increased in hematologic malig-
nancies. For example, Bcl6 overexpression is detected in 40% of diffuse
large B-cell lymphomas (DLBCL) [44], 14% of follicular lymphomas
[45], and 48% of nodular lymphocyte-predominant Hodgkin lym-
phomas [46]. In vivo models of lymphomagenesis have confirmed
Bcl6’s oncogenic potential in this cell lineage. “Knock-in” experiments
in mice that cause Bcl6 overexpression in mature B cells result in lym-
phomas with features resembling human DLBCL [47].
As Bcl6 is primarily associated with normal and abnormal B cell
development, its presence in half of the examined NB tumors was
unexpected. Gene expression profiling and immunostaining studies
document that Bcl6 is detected in a limited number of other types
of cancer including certain skin tumors [48] and breast carcinoma,
where its expression is associated with increased cell survival and arrest
of differentiation [49].
Whether Bcl6 has a role in NB pathogenesis needs to be determined,
although its abilities to protect cells against DNA damage–induced
death and to block differentiation are of clear potential relevance to
NB. Neuroblastoma develops from neural crest cells in which complete
differentiation along the sympathoadrenal lineage is blocked [50];
therefore, it is tempting to speculate that analogous to its role in arrest-
ing B-cell differentiation in normal germinal centers and in DLBCL,
Figure 4. Bcl6 is expressed in human NB tumors. Bcl6 protein expression in NB tumor samples was detected by immunostaining.
Tumors are classified as either N+/S+, N+/S−, N−/S+, or N−/S− based on the detection of Bcl6 (nuclear brown straining) in neuro-
blastic (green arrows) and/or Schwannian stromal rich regions (yellow arrows). Original magnification, ×400.
134 Bcl6 Expression in Neuroblastoma Chamdin et al. Translational Oncology Vol. 2, No. 3, 2009
Bcl6 arrests the differentiation of neural crest cells as a step in the de-
velopment of NB tumors. Bcl6 attenuation of the DNA damage re-
sponse mechanism could promote the genetic instability characteristic
of NB tumors. Understanding the significance of Bcl6 expression in
NB tumor cells will also be furthered by determining the pattern of
Bcl6 expression during normal sympathoadrenal lineage development
to ascertain whether it has a function similar to B cells in blocking
terminal differentiation.
Although the Bcl6 locus (3q27) has been reported in chromosomal
translocations observed in NB [51], 3q abnormalities are not common
in this cancer, and the region encompassing 3q27 is amplified in only
6% of NB tumors [52]. Thus, chromosomal changes do not com-
monly affect Bcl6 expression inNB. Additional experiments are needed,
however, to determine whether point mutations or small deletions in
key regulatory sequences within the Bcl6 gene occur in NB, similar to
those found in B cells that may contribute to its abnormal regulation in
lymphoma [53–55].
Our results indicate that Bcl6 expression in the neuroblastic compo-
nent of NB tumors is associated with low-risk disease and better clinical
outcomes. Bcl6 expression in primary central nervous system lymphoma,
DLBCL, and follicular lymphoma is similarly associated with better
outcomes, including improved overall survival [44,56–58]. Thus, in lym-
phoma where Bcl6 can clearly promote tumorigenesis, its expression in
established disease is, nevertheless, an indicator of favorable outcomes.
One possible explanation for this relationship between expression and
outcome is that Bcl6 increases responsiveness to chemotherapy. Because
Bcl6 attenuates theDNAdamage response that normally arrests cell cycle
progression, its expression may increase drug killing by preventing the
repair of DNA damage induced by chemotherapy resulting in replication
failure. Work is underway to determine whether Bcl6 expression affects
chemosensitivity and DNA repair in NB cell lines. Preliminary experi-
ments using small interfering RNA to knock down Bcl6 in S-type cell
lines have shown that reducing RNA level by more than 50% has no
effect on survival or growth, demonstrating the feasibility of using this
model to study chemoresponsiveness.
Finally, the findings presented here identify opportunities for future
work to elucidate whether Bcl6 expression improves classification for
the purposes of treatment stratification, to determine whether Bcl6 ex-
pression can be regulated to treat this disease and to define the role of
this protein in NB tumor development.
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